CAMBRIDGE, Mass., February 27, 2017 -- Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 6, 2017, from 3:00 -3:25pm EST.

About Mersana Therapeutics                                                          

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients.  Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017.  In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.

###

Media Contact

Paul Kidwell
paulkidwell@comcast.net
617-680-1088

Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
Christina@sternir.com
(212) 362-1200